# Proofline production status — 2026-11-04

NO-GO. Customer intake, live billing and customer delivery remain disabled.
Latest observed database preflight: 6/9 passing after confirmed account acceptance. These are identity/database checks,
not the nine broader A–I production gates; none of those broad gates is fully verified.

## Verified this cycle
- Role-aware remediation/retest workbench and API v2 deployed. 60 Chromium/WebKit
  browser cases, 34 followup contracts, 36 existing Node checks and four migration
  inventory checks pass; all six CI workflows green. Deployed HTML/CSS/JS match
  tested source. Genuine followup acceptance remains unexecuted; see
  FOLLOWUP_WORKBENCH_ACCEPTANCE.md and SALE_READINESS_DECISION.md.
- Synthetic followup API v1 deployed: authenticated append and paginated history,
  32 mocked contract tests, two live gateway denials; 36 existing Node regressions
  and four migration inventory tests pass. No live followup append has been tested.
  See FOLLOWUP_API_ACCEPTANCE.md. Browser controls subsequently completed; live acceptance remains pending.
- Remediation/reverification database layer deployed as migration 20261104200937.
  21 new isolated assertions and 21 existing security checks pass; all seven live
  catalog categories match the 38-migration rebuild. New ledger has no client grants; a server-only staging API was subsequently
  deployed, with UI contracts subsequently verified and live acceptance still pending. See FOLLOWUP_LEDGER_ACCEPTANCE.md for scope and limitations.
- Confirmed owner-controlled accounts: 9 live API authorization/revocation checks
  and Chromium/WebKit role sign-in/report acceptance passed. Auth Site URL now
  points to staging and was verified after dashboard reload.
- Live review acceptance: 25 checks, one browser-created changes_requested decision,
  persisted across both browser engines; collector, approval, altered digest,
  duplicate, replacement and revoked-session attempts denied. Database confirms
  exactly one decision, unchanged artifact digest, draft status, delivery blocked
  and zero sessions. See LIVE_REVIEW_ACCEPTANCE.md.
- Database follow-up (5044d05): all 37 recorded migrations recovered; 35 application
  migrations replay in isolated PostgreSQL, with 2 pg_net operations excluded.
  Seven captured live catalog categories match. 21 SQL security checks and 4 migration
  inventory tests pass; hosted rebuild CI passes. Five ledger TRUNCATE guards and a
  complete report JSON constraint deployed in migration 20261104142004.
- Post-change API rehearsal: 17/17, receipt e719f677-4b38-4afc-a37b-a5d517ffa2e9;
  zero users/sessions/active memberships at that earlier checkpoint (before approved
  account enrollment). Current state retains two active approved role memberships.
- Source baseline: main f329080; recovered staging frontend commit 9dfdaec.
- Historical report 503: not reproduced in fresh live synthetic rehearsal.
  Receipt a2873da6-de93-4621-ad9b-298f2f3cd73e, 17/17 checks, reviewer read 200,
  collector denial 403, bad digest denial, revocation denial, cleanup confirmed.
- pg_net is in extensions. Latest Security Advisor: 13 informational no-policy
  notices and one Auth warning for disabled leaked-password protection.
- Initial browser baseline: Chromium/WebKit, 1440/768/390/320px, no overflow or axe violations.
- Reproduced sign-in focus failure and misleading logout on both engines using mocks.
- Fixed focus, failed-logout messaging, empty successful logout, expired-session reset,
  request timeout/network/503 recovery, assertive announcements and CSP-blocked inline styling.
- Local existing suites: 15 Python gateway + 7 public-page tests + 47 Node tests passed.
- New browser suite separates actual rendering from mocked identity/report interactions.
  See web-tests/results and the deployment acceptance record for final counts.

Limitations: no independent human reviewer acceptance; no live Graph collection; no full customer
journey, payment sandbox, independent production key custody or production recovery.
No customer or revenue success is claimed. Price hypotheses remain $1,500 scoped
review / $1,250 monthly assurance, subject to validation.
